Supplementary Figure 2 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells

Figure S2. Lurbinectedin inhibits RNA synthesis and promotes Pol II degradation in different cancer cell lines. (A) Kinetics of RNA synthesis. Ewing sarcoma (A673), colon (HCT-116), cervix (HeLa) and breast (MDA-MB-231) cancer cells were treated with lurbinectedin or vehicle (DMSO) in normal growth medium for 0, 30, 45, 60, 90 and 120 minutes and pulsed with 5µCi/ml [3H] uridine for 30min. Data are mean {plus minus} SEM values (triplicates, n=1). (B) Western blot analyses of Pol II in the same panel of cancer cell lines after 1, 2, 3 or 4 hours of lurbinectedin (30nM) treatment.